Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.
JD Powderly, B Chmielowski, JR Brahmer… - 2020 - ascopubs.org
TPS3163 Background: Regulatory T cells (Treg) can dampen anti-tumor immune responses
in the tumor microenvironment (TME). The predominant chemokine receptor on human Treg …
in the tumor microenvironment (TME). The predominant chemokine receptor on human Treg …
Phase 1/2 dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer
JD Powderly II, B Chmielowski, JR Brahmer… - rapt.com
METHODS ABSTRACT Preclinical Dataa BACKGROUND References Phase 1 Healthy
Volunteer Datab Patient Selection: “Charged” and Vi Page 1 Major Eligibility Criteria …
Volunteer Datab Patient Selection: “Charged” and Vi Page 1 Major Eligibility Criteria …
Phase 1/2 dose escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer
JD Powderly II, B Chmielowski, JR Brahmer… - rapt.com
METHODS ABSTRACT Preclinical Dataa BACKGROUND References Phase 1 Healthy
Volunteer Datab Patient Selection: “Charged” and Vi Page 1 Major Eligibility Criteria …
Volunteer Datab Patient Selection: “Charged” and Vi Page 1 Major Eligibility Criteria …